FERRER
The international pharmaceutical BCorp company Ferrer continues to strengthen its focus on pulmonary vascular and interstitial lung diseases by announcing the expansion of its current distribution agreement with United Therapeutics Corporation (Nasdaq: UTHR) for Tyvaso® (treprostinil inhalation solution*) – a pharmaceutical drug-device combination product authorized for the treatment of WHO Group 3 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), and for WHO Group 1 Pulmonary Arterial Hypertension (PAH).
Both companies have signed the distribution rights for two new potential indications of the molecule, Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF), two rare diseases characterized by scarring of lungs which results in difficulty for patients to breathe, leading to poor quality of life and even death. Current available treatments for IPF and PPF have only been shown to slow disease progression, whereas treprostinil inhalation solution could potentially offer a new treatment option in these patients.
“The pulmonary vascular and interstitial lung diseases field is very important for us”, said Oscar Pérez, Chief Scientific and Business Development Officer at Ferrer. “Strengthening our partnership with United Therapeutics Corporation can advance our purpose of using business to fight for social justice through the delivery of new solutions for people, families and caregivers living with devastating diseases”.
Under the expanded agreement, Ferrer has been appointed as the exclusive, worldwide distributor (except for the US, Canada, Japan, China, and Israel), to make this therapeutic option available upon approval for the treatment of IPF and PPF and keep delivering transformative solutions to the patients in need.
The announcement leverages Ferrer’s strong capabilities and expertise in pulmonary vascular and interstitial lung diseases and underscores both companies’ commitment to expanding global access to treprostinil inhalation solution for IPF and PPF patients, if approved.
Treprostinil inhalation solution is currently being assessed in three Phase 3 clinical trials: two in IPF patients (with over 1.000 subjects combined), and one in PPF patients (with 698 subjects), with a 52-week follow-up and collectively covering a global study geography.
* Treprostinil inhalation solution is a prostacyclin mimetic indicated for the treatment of Pulmonary arterial hypertension (PAH; WHO Group 1) and Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3). Tyvaso® for PH-ILD is currently authorized in the US, Israel, Chile, Dominican Republic, and Argentina, and under regulatory review in Japan, and for WHO Group 1 Pulmonary Arterial Hypertension (PAH), currently authorized in the US, Israel, Argentina, Colombia, Japan, and Dominican Republic. Regarding the registration of Tyvaso® (treprostinil) inhalation solution for the treatment of PH-ILD, Ferrer has just obtained the marketing authorization in Chile and Dominican Republic and will focus on obtaining it in the United Kingdom as well. Further assessment of Tyvaso® PH-ILD for the European Union will continue.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528462230/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Settles Pending Litigation13.2.2025 13:00:00 CET | Press release
Kinaxis® (TSX: KXS), a global leader in end-to-end supply chain orchestration, has entered into a settlement agreement with Blue Yonder Group, Inc. to fully resolve all pending litigation matters between the companies which includes Blue Yonder’s patent infringement claims and Kinaxis’ trade secret misappropriation counterclaims. The terms of the settlement agreement are confidential. About Kinaxis Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™ combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please
Flowchem Strengthens Leadership Team, Appointing COO, Technology Team, and Board of Senior Industry Experts13.2.2025 13:00:00 CET | Press release
Flowchem (“Flowchem” or the “Company”) and SCFPartners (“SCF”) are pleased to announce several personnel additions. Flowchem is a leading global player in the drag reducing agent (“DRA”) market, providing custom-engineered specialty chemicals to help customers around the world optimize the performance of their infrastructure. These key appointments bolster the already-strong management team in place at the time of the Company’s acquisition in 2024, positioning it for continued growth and industry leadership. Shivali Agarwal has been appointed as Chief Operating Officer (“COO”). Shivali brings decades of industry operating experience in roles across the globe, most recently serving as Group General Manager, Production Systems at SLB (NYSE:SLB). Shivali holds a Master of Business Administration from Harvard Business School and a Master of Science in Biological Sciences and a Bachelor of Science in Chemical Engineering from the Birla Institute of Technology & Science, Pilani, India. Flowc
Infobip Joins EU Initiative to Boost Europe's Global Competitiveness13.2.2025 12:47:00 CET | Press release
Global cloud communications platform Infobip has officially signed the contract to join the IPCEI-CIS project, an EU-led initiative to create the next-generation global communications platform to increase Europe's international competitiveness. The signing took place at Infobip's campus in Zagreb, where Croatian Prime Minister Andrej Plenković participated in the event alongside Infobip's CEO Silvio Kutić. With this project, Europe aims to safeguard its digital and technological sovereignty, as many existing models that dominate the cloud infrastructure sector do not often align with EU data protection and transparency regulations. Croatian Prime Minister Andrej Plenković said: "Infobip is an example of Croatian technological excellence and global success. Its entry into the Project of Common European Interest (IPCEI) confirms its key role in European digital infrastructure. This project helps create a secure cloud infrastructure, supporting industries, companies, and public services a
Ricardo Signs Deal to Support Singer With Bespoke Manual Transmissions13.2.2025 10:00:00 CET | Press release
Ricardo has signed a multi-year deal to supply transmissions for Porsche 911s reimagined by Singer Ricardo, a global strategic, environmental, and engineering consulting company, has signed a deal to supply bespoke, manual transmissions to Singer’s operations in the US and UK. The transmissions will be exclusive to Singer and will initially be available to owners who request Singer’s Classic Turbo or DLS Turbo restoration services for their Type 964 Porsche 911. Singer arrived on the automotive scene with their Classic services in 2009. Since then, the company has developed restoration services allowing owners to personalise both naturally aspirated and turbocharged cars. A Porsche 911 Reimagined by Singer is a rare machine, bringing together iconic design with twenty-first century engineering and material science. Ricardo’s design team will ensure that the transmissions meets the exacting, high performance needs of Singer’s clients. The focus is on delivering an H-pattern transmission
Xsolla Partners With Day of the Devs for 2025 to Support New Game Development and Launches at Key Events13.2.2025 10:00:00 CET | Press release
Day Of The Devs Powered By Xsolla Will Celebrate Creativity And Bring Opportunities Together For Game Developers Of All Genres, Backgrounds, And Locations Xsolla, a leading global video game commerce company, announces its 2025 flagship sponsorship for Day of the Devs, a non-profit organization celebrating video games' creativity, diversity, and magic. This announcement underscores Xsolla's commitment to empowering game developers and bringing together opportunities for creative talent and development worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213515388/en/ (Graphic: Xsolla) “This partnership and collaboration underscores our ongoing mission to empower developers and make great games more accessible worldwide no matter what size or where they are from,” said Berkley Egenes, Chief Marketing & Growth Officer. “Day of the Devs powered by Xsolla provides an unparalleled platform to support diverse talent and cr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom